Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: The significance of baseline glomerular filtration rate

Journal of Heart and Lung Transplantation

Volumn 31, Issue 3, 2012, Pages 259-265

  Arora, Satish ^a   Gude, Einar ^a   Sigurdardottir, Vilborg ^b   Mortensen, Svend Aage ^c   Eiskjær, Hans ^c   Riise, Gerdt ^b   Mared, Lena ^d   Bjørtuft, Øystein ^a   Ekmehag, Bjørn ^d   Jansson, Kjell ^e   Simonsen, Svein ^a   Aukrust, Pl ^a,g   Solbu, Dag ^f   Iversen, Martin ^c   Gullestad, Lars ^a,g  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f Novartis Norge   (Norway)

^g UNIVERSITY OF OSLO   (Norway)

Author keywords

CNI reduction; everolimus; GFR improvement; heart and lung transplantation; renal failure; thoracic transplantation

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ARTICLE; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; STANDARD; TREATMENT OUTCOME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RENAL INSUFFICIENCY; SCANDINAVIA; SIROLIMUS; TACROLIMUS; TIME FACTORS;

EID: 84856872316     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2011.12.010     Document Type: Article

References (20)

1. R.D. Bloom, P.P. Reese Chronic kidney disease after nonrenal solid-organ transplantation J Am Soc Nephrol 18 2007 3031 3041 (Pubitemid 350223963)
2. S. Arora, A. Andreassen, S. Simonsen Prognostic importance of renal function 1 year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy Transplantation 84 2007 149 154 (Pubitemid 47205747)
3. A.O. Ojo, P.J. Held, F.K. Port Chronic renal failure after transplantation of a nonrenal organ N Engl J Med 349 2003 931 940 (Pubitemid 37064766)
4. J.M. Campistol, S.H. Sacks Mechanisms of nephrotoxicity Transplantation 69 2000 SS5 SS10
5. M. Cantarovich Renal protective strategies in heart transplant patients Curr Opin Cardiol 22 2007 133 138 (Pubitemid 46220269)
6. M. Pascual, J. Curtis, F.L. Delmonico A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation Transplantation 75 2003 1501 1505 (Pubitemid 36597285)
7. S.M. Flechner, J. Kobashigawa, G. Klintmalm Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity Clin Transplant 22 2008 1 15 (Pubitemid 351149996)
8. R.T. Abraham Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling Curr Opin Immunol 10 1998 330 336 (Pubitemid 28286960)
9. A.I. Sanchez-Fructuoso Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials Expert Opin Drug Metab Toxicol 4 2008 807 819 (Pubitemid 352003202)
10. L. Gullestad, M. Iversen, S.A. Mortensen Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial Transplantation 89 2010 864 872
11. E. Gude, L. Gullestad, S. Arora Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation J Heart Lung Transplant 29 2010 641 647
12. M. Rothenburger, A. Zuckermann, C. Bara Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference J Heart Lung Transplant 26 2007 305 311 (Pubitemid 46498769)
13. A.O. Zuckermann, A.Z. Aliabadi Calcineurin-inhibitor minimization protocols in heart transplantation Transpl Int 22 2009 78 89
14. A. Saurina, J.M. Campistol, C. Piera Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria Nephrol Dial Transplant 21 2006 488 493 (Pubitemid 43160007)
15. L. Straathof-Galema, J.F. Wetzels, H.B. Dijkman, E.J. Steenbergen, L.B. Hilbrands Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism Am J Transplant 6 2006 429 433 (Pubitemid 43382183)
16. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461 470 (Pubitemid 29135798)
17. F.P. Schena, M.D. Pascoe, J. Alberu Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial Transplantation 87 2009 233 242
18. A.S. Levey, J. Coresh, E. Balk National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification Ann Intern Med 139 2003 137 147
19. H.B. Lehmkuhl, D. Mai, M. Dandel Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients J Heart Lung Transplant 26 2007 700 704 (Pubitemid 47007710)
20. P. Stratta, C. Canavese, M. Quaglia Posttransplantation chronic renal damage in nonrenal transplant recipients Kidney Int 68 2005 1453 1463 (Pubitemid 43169892)